SG10201913963RA - Amatoxin-antibody conjugates - Google Patents

Amatoxin-antibody conjugates

Info

Publication number
SG10201913963RA
SG10201913963RA SG10201913963RA SG10201913963RA SG10201913963RA SG 10201913963R A SG10201913963R A SG 10201913963RA SG 10201913963R A SG10201913963R A SG 10201913963RA SG 10201913963R A SG10201913963R A SG 10201913963RA SG 10201913963R A SG10201913963R A SG 10201913963RA
Authority
SG
Singapore
Prior art keywords
amatoxin
antibody conjugates
conjugates
antibody
Prior art date
Application number
SG10201913963RA
Inventor
Jan Anderl
Torsten Hechler
Christoph Mueller
Andreas Pahl
Original Assignee
Heidelberg Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Gmbh filed Critical Heidelberg Pharma Gmbh
Publication of SG10201913963RA publication Critical patent/SG10201913963RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
SG10201913963RA 2015-03-09 2016-03-07 Amatoxin-antibody conjugates SG10201913963RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15000681 2015-03-09

Publications (1)

Publication Number Publication Date
SG10201913963RA true SG10201913963RA (en) 2020-03-30

Family

ID=52648788

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201707054PA SG11201707054PA (en) 2015-03-09 2016-03-07 Amatoxin-antibody conjugates
SG10201913963RA SG10201913963RA (en) 2015-03-09 2016-03-07 Amatoxin-antibody conjugates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201707054PA SG11201707054PA (en) 2015-03-09 2016-03-07 Amatoxin-antibody conjugates

Country Status (25)

Country Link
US (1) US10842882B2 (en)
EP (2) EP4115910A1 (en)
JP (2) JP6863900B2 (en)
KR (1) KR20180003537A (en)
CN (2) CN107636016B (en)
AU (1) AU2016228415B2 (en)
BR (1) BR112017019300B1 (en)
CA (1) CA2978064A1 (en)
DK (1) DK3268047T3 (en)
ES (1) ES2968012T3 (en)
FI (1) FI3268047T3 (en)
HR (1) HRP20240075T1 (en)
HU (1) HUE064698T2 (en)
IL (2) IL254108B (en)
LT (1) LT3268047T (en)
MX (1) MX2017011281A (en)
NZ (1) NZ734892A (en)
PL (1) PL3268047T3 (en)
PT (1) PT3268047T (en)
RS (1) RS64955B1 (en)
RU (1) RU2724328C2 (en)
SG (2) SG11201707054PA (en)
SI (1) SI3268047T1 (en)
WO (1) WO2016142049A1 (en)
ZA (1) ZA201705770B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3215519A1 (en) 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
LT3268047T (en) * 2015-03-09 2023-11-10 Heidelberg Pharma Research Gmbh Amatoxin-antibody conjugates
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
SG11201811290VA (en) 2016-06-17 2019-01-30 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+cells
JP2019522050A (en) 2016-06-17 2019-08-08 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Compositions and methods for cell depletion
MX2019007604A (en) 2016-12-23 2019-08-16 Heidelberg Pharma Res Gmbh Amanitin antibody conjugates.
WO2018134787A2 (en) 2017-01-20 2018-07-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd137+ cells
EP3665173A1 (en) 2017-08-07 2020-06-17 Heidelberg Pharma Research GmbH Novel method for synthesizing amanitins
AU2018317611B2 (en) * 2017-08-18 2022-03-10 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Non-natural amatoxin-type antibody conjugate
WO2019047941A1 (en) * 2017-09-08 2019-03-14 四川百利药业有限责任公司 Amanitin antibody conjugate
JP7389022B2 (en) * 2017-09-22 2023-11-29 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング PSMA-targeted amanitin conjugate
CN111601616A (en) 2017-10-24 2020-08-28 美真达治疗公司 Compositions and methods for depleting CD117+ cells
US10899843B2 (en) * 2017-10-24 2021-01-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
SG11202004294XA (en) * 2017-11-29 2020-06-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd5+ cells
CN113683622A (en) 2017-12-15 2021-11-23 四川科伦博泰生物医药股份有限公司 Bioactive substance conjugate and preparation method and application thereof
US20210077571A1 (en) 2018-04-13 2021-03-18 Heidelberg Pharma Research Gmbh Targeted amatoxin conjugate for the treatment of solid tumors
CN112739339A (en) * 2018-07-23 2021-04-30 美真达治疗公司 Use of anti-CD 137 Antibody Drug Conjugates (ADCs) in allogeneic cell therapy
MX2021004231A (en) * 2018-10-23 2021-06-15 Magenta Therapeutics Inc Fc silenced antibody drug conjugates (adcs) and uses thereof.
AU2020228060A1 (en) * 2019-02-27 2021-09-16 Angiex, Inc. Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
BR112021023226A2 (en) 2019-05-23 2022-01-04 Heidelberg Pharma Res Gmbh Compound, conjugate, method for synthesizing the conjugates and pharmaceutical composition
AR120218A1 (en) * 2019-10-15 2022-02-02 Heidelberg Pharma Res Gmbh AMATOXIN AND B LYMPHOCYTE SPECIFIC ANTIBODY CONJUGATES
CN111308100B (en) * 2020-04-13 2023-04-21 北京维德维康生物技术有限公司 ELISA kit for detecting beta-amatoxin and preparation and application thereof
US20230220001A1 (en) 2020-06-09 2023-07-13 Heidelberg Pharma Research Gmbh Method for synthesis of thioether-containing peptides
WO2021255217A1 (en) 2020-06-19 2021-12-23 Heidelberg Pharma Research Gmbh Amatoxin and amatoxin conjugates for use in inhibition of rna virus replication
JP2023548522A (en) 2020-11-04 2023-11-17 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング Composition for use in cancer treatment comprising a combination of an immune checkpoint inhibitor and an antibody-amatoxin conjugate
IL304966A (en) 2021-03-19 2023-10-01 Heidelberg Pharma Res B-Lymphocyte Specific Amatoxin Antibody Conjugates
AR125473A1 (en) * 2021-04-29 2023-07-19 Abbvie Inc ANTI-C-MET ANTIBODY AND DRUG CONJUGATES
IL308163A (en) 2021-05-03 2024-01-01 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
CN113980909B (en) * 2021-11-16 2022-06-14 江南大学 Alpha-amanitin artificial antigen, monoclonal antibody, hybridoma cell strain and application
US20230355792A1 (en) 2022-04-07 2023-11-09 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index
WO2024094688A1 (en) 2022-11-01 2024-05-10 Heidelberg Pharma Research Gmbh Anti-gucy2c antibody and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
ES2371085T3 (en) 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. USE OF AMATOXIN OR FALOTOXIN CONJUGATES WITH MACROMOLECULES FOR TUMOR THERAPY AND INFLAMMATION.
PL2099823T5 (en) * 2006-12-01 2023-02-20 Seagen Inc. Variant target binding agents and uses thereof
EP3485912A1 (en) 2009-04-08 2019-05-22 Faulstich, Heinz, Dr. Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
RU2011145038A (en) 2009-04-08 2013-05-20 Дойчес Кребсфоршунгсцентрум AMATOXIN-BEARING TARGET-BINDING MOLECULES FOR CANCER TREATMENT
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
PE20130342A1 (en) 2010-04-15 2013-04-20 Spirogen Sarl PIRROLOBENZODIACEPINES AND CONJUGATES OF THE SAME
ES2402254T3 (en) * 2010-09-30 2013-04-30 Heidelberg Pharma Ag Amatoxin conjugates with improved linkers
US20150218220A1 (en) * 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
EP2774624A1 (en) * 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
AU2014244245C1 (en) 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
EA201690195A1 (en) 2013-08-12 2016-05-31 Дженентек, Инк. ANTIBODY CONJUGATE CONNECTIONS ON THE BASIS OF DIMER 1- (HLORMETHYL) -2,3-DIGYDRO-1H-BENZO [E] INDOL AND METHODS OF APPLICATION AND TREATMENT
CA2938450C (en) * 2014-02-11 2023-10-17 Seattle Genetics, Inc. Selective reduction of proteins
EP3215519A1 (en) * 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
LT3268047T (en) * 2015-03-09 2023-11-10 Heidelberg Pharma Research Gmbh Amatoxin-antibody conjugates
EA202192137A1 (en) * 2019-01-31 2021-10-25 Ханчжоу Дэк Биотек Ко., Лтд AMATOXY ANALOGUE CONJUGATE WITH BRANCHED LINKERS
SG11202110287QA (en) * 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof

Also Published As

Publication number Publication date
US10842882B2 (en) 2020-11-24
CN107636016B (en) 2022-02-11
RU2724328C2 (en) 2020-06-23
HUE064698T2 (en) 2024-04-28
JP2021100974A (en) 2021-07-08
LT3268047T (en) 2023-11-10
ZA201705770B (en) 2022-02-23
JP7083935B2 (en) 2022-06-13
FI3268047T3 (en) 2023-12-21
RU2017132185A3 (en) 2019-05-23
EP3268047B1 (en) 2023-10-18
KR20180003537A (en) 2018-01-09
PT3268047T (en) 2023-12-05
CN114395050A (en) 2022-04-26
DK3268047T3 (en) 2024-01-02
AU2016228415A1 (en) 2017-09-14
IL285516B (en) 2022-04-01
IL254108A0 (en) 2017-10-31
ES2968012T3 (en) 2024-05-06
NZ734892A (en) 2023-03-31
PL3268047T3 (en) 2024-03-18
RU2017132185A (en) 2019-04-09
WO2016142049A1 (en) 2016-09-15
US20180043033A1 (en) 2018-02-15
CN107636016A (en) 2018-01-26
BR112017019300A2 (en) 2018-05-08
SI3268047T1 (en) 2024-02-29
EP4115910A1 (en) 2023-01-11
IL285516A (en) 2021-09-30
BR112017019300B1 (en) 2023-02-23
MX2017011281A (en) 2018-05-15
HRP20240075T1 (en) 2024-03-29
AU2016228415B2 (en) 2021-04-01
EP3268047B9 (en) 2024-01-10
SG11201707054PA (en) 2017-09-28
CA2978064A1 (en) 2016-09-15
JP6863900B2 (en) 2021-04-21
RS64955B1 (en) 2024-01-31
JP2018513120A (en) 2018-05-24
IL254108B (en) 2021-09-30
EP3268047A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
IL285516B (en) Amatoxin-antibody conjugates
ZA201904269B (en) Pyrrolobenzodiazepine-antibody conjugates
ZA201704297B (en) Pyrrolobenzodiazepine-antibody conjugates
HUE055424T2 (en) Antibody-fynomer conjugates
PL3544636T3 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201513607D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) Pyrrolobenzodiazepine-antibody conjugates
HK1257229A1 (en) Cck2r-drug conjugates
PT3270711T (en) Sugar-dipeptide conjugates
SG10201506686WA (en) Conjugates
GB201721290D0 (en) Conjugates
GB201719906D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201719398D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201719393D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201719391D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201706466D0 (en) pyrrolobenzodiazepine-peptide conjugates
GB201518839D0 (en) Conjugates
GB201702029D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201513605D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201517852D0 (en) Novel compounds and conjugates
GB201420910D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201406717D0 (en) Pyrrolobenzodiazepine-Antibody conjugates
GB201406718D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201406719D0 (en) Pyrrolobenzodiaepine-antibody conjugates
GB201406720D0 (en) Pyrrolobenzodiazepine-antibody conjugates